JWM
ALXN

Janiczek Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Janiczek Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68
Closed -$12K – 1053
2021
Q2 		$12K Buy
68
+20
+42% +$3.43K ﹤0.01% 537
2021
Q1 		$7K Buy
48
+32
+200% +$4.95K ﹤0.01% 600
2020
Q4 		$2K Buy
16
+6
+60% +$771 ﹤0.01% 703
2020
Q3 		$1K Sell
10
-7
-41% -$755 ﹤0.01% 628
2020
Q2 		$2K Buy
+17
New +$1.8K ﹤0.01% 322

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Janiczek Wealth Management's ALXN Position: Q3 2021 in Review

Janiczek Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 68 shares — an estimated $12K sold.

Janiczek Wealth Management first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $12K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Janiczek Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Janiczek Wealth Management sold 68 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12K.
  • Janiczek Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Janiczek Wealth Management's Alexion Pharmaceuticals position peaked at $12K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Janiczek Wealth Management's 13F filing for Q3 2021, filed 19 Oct 2021.